Portfolio articles – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

Aboleris Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer

2025.10.302025.11.03 / Gosselies, Belgium and Nantes, France, October 30, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering f ...

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

2025.10.132025.10.13 / THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical t ...

Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer

2025.10.072025.10.07 / Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovaria ...

AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025

2025.09.172025.09.22 / Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announced that its ongoing Phase 2a study of ...

ARTHEx biotech

ARTHEx Biotech Upsizes Series B Financing Round to $87M

2025.09.172025.09.22 / to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines - Extension financing led by new investor Bpifrance, with renewed participation from al ...

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

2025.09.162025.09.22 / Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone ...

AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer

2025.09.022025.09.22 / Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces to ...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

2025.06.252025.09.22 / Orally administered treatment was well tolerated, with early signs of clinical activity In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting

2025.05.092025.09.22 / First small molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in ...

AbolerIS Pharma Announces Formation of Scientific Advisory Board

2025.04.292025.04.30 / Gosselies, Belgium and Nantes, France, April 24, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering fro ...

Maximizing value when developing oncolytic viral therapy

2025.04.012025.04.30 / As the new CEO for Theolytics, David Apelian aims to take full advantage of the first clinical studies for the company’s lead product. The UK-based biotech has a whole potential platform for creating ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting

2025.03.102025.04.30 / Nck modulator reduced evidence of inflammation in an animal model of dermal irritation Compelling preclinical data support continued development of Nck modulators in atopic dermatitis Cambridge ...